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studies, including and in addition to the EQ-5D, are extracted and added to the data-
base record to create a searchable index of instruments. A beta version of the data-
base, using bespoke software to improve functionality, is currently undergoing ad hoc 
testing. Results: The alpha version of the database contains over 3,500 potentially 
relevant studies identified by the search process. Several hundred studies have been 
data extracted and indexed. The names of over 50 instruments, including quality of 
life, disease specific and generic preference-based measures have been added to the 
index. A programme of sifting, data extraction and indexing is ongoing. Public access 
to the beta version of the database is planned for Autumn 2013. ConClusions: 
The purpose of the health utilities database is to improve access to HSUV evidence, 
in the first instance in studies using the EQ-5D with a view to including all major 
preference-based utility measures.
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objeCtives: To analyze the publications on methodology and normative regu-
lations of pharmacoeconomic studies, including materials providing results of 
conducted researches in Russia or translated international publications, as well 
as to analysis the dynamics of publications and identify the structure of meth-
odological approaches in Russia. Methods: The screening of publications from 
the data of the Central Medical Scientific Library of the First MSMU was conducted 
based on the key words - “pharmacoeconomic*” and “pharmacoeconomical*” with 
corresponding endings. The time horizon of the study was 6 years (from 2007-
2012). Results: By the beginning of 2013, 280 literature sources were found and 
analyzed in the timeline from 2007 to 2013. It was found that the most common 
type of publications for the reporting period have been the inaugural dissertations 
showing the researches results - they are accounted for about 47% of all studies, 
followed by further research reports, accounted for 44%, methodical publications 
- 5%, dissertations devoted to the methodology of the pharmacoeconomics- 3%, 
regulatory guidance documents and translations of foreign studies - 1%. The most 
common structure of published researches was monocenter (56%), with a retro-
spective time-restricted directivity (74%). Russian authors use the methodology of 
the “cost-effectiveness” analyzing in their works the most frequently (48%). 64% of 
Russian researchers take into account only direct costs, 32% of researchers analyze 
their studies based on indirect costs. ConClusions: Based on our review of the 
published works from 2007 to 2012, we can make a conclusion on the formation 
and development of high-grade pharmacoeconomics as an independent research 
area in the Russian Federation.
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evaluaTing DiffeRenT MoDes of RaDioTheRaPy baseD on a PaTienT-
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objeCtives: Use of proton instead of photon radiation therapy for head and neck 
cancer reduces the primary tumor and damage to adjacent organs risk, which 
results in fewer complications. These complications decrease quality of life (QOL). To 
support better decision making concerning which patients benefit most from pro-
ton therapy, a patient-level simulation model is developed and applied to compare 
outcomes. Methods: Model estimates, such as patient and tumor characteristics, 
follow-up time, and survival, were based on patient-level data containing patients 
treated with radiation therapy as first line therapy for head and neck tumor in The 
Netherlands between 1980–2010 at the UMC Groningen (n= 277) and VU Amsterdam 
(n= 736). In silico radiation treatment planning schemes for both proton and photon 
therapy allowed to compare a priori expected health benefits and cost consequences 
for both therapy modes to support a patient tailored choice. Results: Patients 
experienced their first event at a median time of 30 (0-270, SD 34) months’ time. 
Loco-regional recurrency in 29%, distant metastasis in 4.2%, both combined in 1% 
and dead in 13.3% of patients. Cost per year for photon was estimated € 15000, proton 
€ 30000, disease free state € 190, local regional recurrence € 28000, metastases € 35000, 
and both € 35000. For the complication sticky saliva costs per year of an average 
patient were € 31, xerostomia € 194, dysphagia € 57, tube feeding € 4262, and hypothy-
roidism € 117. Proton radiation therapy leads to less complications and improved 
QOL. ConClusions: Given the high costs of proton therapy, this was found not 
to be cost-effective compared to best photon therapy in an average patient with 
head and neck cancer. However, the outcomes vary substantially between patients. 
Depending on patient and tumor characteristics for selected patients with high 
complication risks, proton therapy can be a better option.
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objeCtives: To assess the overall impact of the production and distribution of 
pharmaceutical products in the Greek economy, in terms of Value Added, GDP, 
employment and tax revenues. Methods: The overall impact in the Greek econ-
omy is estimated as an exogenous change in the economic activity by using the 
Leontief input-output model. Results: The results indicate that the direct effect 
of the industry on domestic economic activity is € 1.5 billion in terms of GDP. The 
indirect effect, which represents the value created by auxiliary sectors as (main 
suppliers) of the pharma industry is € 2.2 billion. Finally, the induced effect, which 
is the impact from the final consumption, as a result of the wages and salaries 
gained by employees across the production chain of the specific industry is € 3.8 
billion. Hence, the overall effect on GDP is approximately € 7.5 billion, which repre-
and nearly half originated from north America (31/69). Emerging themes suggest 
that better accuracy is achieved when patients are answering questions about inpa-
tient and specialist care. ConClusions: There is only a limited amount of valid-
ity and reliability information available to inform best practice for resource-use 
measurement in clinical trials. This ongoing review will identify the gaps, giving a 
clearer view of where research efforts should be concentrated.
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fuTuRe cosTs inclusion in PublisheD econoMic evaluaTions: whaT is 
The cuRRenT siTuaTion?
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objeCtives: Nowadays, there is a general agreement about the need of includ-
ing future related medical costs in life years gained while no consensus has been 
achieved about future unrelated medical costs (indirect medical costs) and future 
non-medical costs. The aim of this study has been to assess the extension of 
published economic evaluations that incorporated future costs and what types 
of future cost were included. Methods: Three general health economic journals 
(Pharmacoeconomics, Value in Health and European Journal of Health Economics) were 
reviewed to identify economic evaluations from 2008 to 2011. Only complete eco-
nomic evaluations were accepted for this research. From each selected article, future 
cost inclusion was evaluated along with the type of future costs included. Results: 
A total of 148 articles were founded from the three journals fulfilling the inclusion 
criteria; 67 of them (45.27 %) incorporated future related medical costs, 9 (6.08 %) 
included also future unrelated medical costs and none included future non-medical 
costs. Percentage of articles including future costs increased from 2008 (33 %) to 
2011(57 %) and no differences were detected between the three journals in the pro-
portion of economic evaluations incorporating future costs. ConClusions: Despite 
most of health economic guidelines advice the need of incorporating future costs in 
l economic evaluations, less than the half of articles reviewed incorporated them. 
Moreover, the inclusion of future unrelated medical costs and future non-medical 
costs was much lower. Results of economic evaluations can change dramatically 
depending on future costs inclusion. It is necessary to change the current practice 
and systematically include future related medical costs in the base case of economic 
evaluations and future unrelated medical costs and future non medical costs at 
least in sensitivity analysis.
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objeCtives: A range of linked electronic health records (LEHR) datasets are 
becoming available in the NHS in England. Understanding the benefits such large 
LEHR datasets can offer when performing cost-effectiveness analysis and over-
coming the challenges inherent in utilising such datasets using as a case study: 
the CALIBER (Cardiovascular Disease Research using Linked Bespoke Studies and 
Electronic Records) dataset to assess the cost-effectiveness of treatment of patients 
with chronic stable angina. Methods: The CALIBER dataset links primary care 
data from CPRD with secondary care data from HES, mortality data from ONS and 
disease-specific data from MINAP. This dataset is used to provide a generalisable 
baseline for cost-effectiveness models and to provide effectiveness estimates for 
treatments observed in the dataset. It is also used to explore decisions that, due 
to ethical concerns, could not be researched through RCTs - for example, optimal 
durations and combinations of treatments used in current practice. The statistical 
methods of matching, differences in differences and instrumental variables are 
used to overcome the selection bias problems associated with inferring treatment 
effects using observational data. The models are also combined with RCT results 
for novel treatments to assess their cost-effectiveness in a real world as opposed to 
trial setting. Results: There were significant challenges involved in working with 
LEHR ranging from correctly linking the data to plausibly imputing missing data 
and correcting for selection bias in estimates. Having addressed these challenges 
we were left with a rich dataset, from which to estimate costs, risks of health events 
and treatment effects in a generalisable real world setting. ConClusions: While 
the selection biases associated with the use of LEHR within the NHS makes them 
challenging to work with, the large sample sizes, generalisability of the results 
and relatively low cost of the research makes them a hugely valuable resource for 
economic evaluation.
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DeveloPMenT of The schaRR huD (healTh uTiliTies DaTabase)
Rees A., Paisley S., Brazier J., Cantrell A., Poku E., Williams K.
University of Sheffield, Sheffield, UK
objeCtives: The retrieval of studies containing evidence of health state utility val-
ues (HSUVs) is currently problematic using generic bibliographic databases such as 
Medline. This is due to a lack of standardised search vocabulary and inadequate and 
inconsistent indexing. The objective of this project is to develop a bibliographic data-
base providing access to details of research studies containing health state utility val-
ues generated using the EQ-5D and other preference-based instruments. Methods: 
The initial phase of the project has focussed on the EQ-5D. An alpha version of the 
database was created using Mendeley reference management software. A corpus of 
potentially relevant studies was identified by searching Medline and by sifting the 
reference lists of systematic reviews of HSUVs in a range of diseases and conditions. 
The sifting of retrieved studies is an ongoing process. Studies are included in the 
database if they contain estimates of HSUVs. The names of instruments used in the 
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2012. The aim of this study is to understand which of the validation methods recom-
mended in health economics and financial guidelines are practically used across 
different disease areas and business fields. Methods: For this study we reviewed 
guidelines, economic models for diabetes, cardiovascular diseases, and cancers, as 
well as risk-prediction models. The identified validation methods were collected 
and categorized into three groups: face validity, internal verification, and cross 
validity. Results: Twenty-two (22) economic models, 8 risk prediction models, 5 
financial and 7 health economics guidelines were identified. In the guidelines we 
found 3, 14 and 5 methods within the face validity, internal verification, and external 
validity categories respectively. Almost three quarters of the 22 methods identi-
fied were also described in the ISPOR guideline on model validation and the other 
guidelines described 5 to 15 methods. External validation was done for 14 out of the 
22 economic models reviewed in which (part of) the model results were compared 
against other clinical/epidemiology studies (14 models) or other validated models 
(10 models). Internal verification was mainly done through comparison against the 
trials that the models were built on (10 models). Out of the remaining 13 internal 
verification methods only 3 were performed for the economic models. Face valida-
tion was only performed for 3 economic models. ConClusions: This study found 
that there is a substantial gap between the validation steps recommended and those 
actually performed. Hence a more consistent and pragmatic approach needs to be 
taken to validate economic models. In addition, the validation methods performed 
need to be consistently reported.
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analysis of healTh caRe cosTs in elDeRly PaTienTs wiTh MulTiPle 
chRonic conDiTions using a finiTe MixTuRe of geneRalizeD lineaR 
MoDels
Eckardt M., Brettschneider C., van den Bussche H., König H.H.
University Medical Center Hamburg, Hamburg, Germany
objeCtives: Multimorbid individuals consume a disproportionally large share 
of health care resources. Usually standard (1-component) regression techniques 
are applied to analyse costs in samples of patients with multiple chronic condi-
tions. However, the patient specific number and combination of co-occurring single 
diseases results in inhomogeneous data leading to biased estimates when using 
traditional regression techniques. In this study we analyse health care costs in a 
sample of patients suffering from multimorbidity using a more elaborate approach 
to address this heterogeneity. Methods: We used a subsample of N= 1050 patients 
from a multicentre prospective cohort study of multimorbid primary care patients 
aged 65 to 85 years in Germany who completed a questionnaire on health care utili-
zation covering a 6-month-period. We applied a finite mixture of generalized linear 
models, which belongs to the group of statistical learning algorithms, in order to 
control for unobserved heterogeneity of patient level health care costs focussing on 
the identification of multimorbidity patterns. Results: We detected four different 
groups of patients with regard to total costs. The effect of the presence of an addi-
tional disease on costs differs between these groups. Two diametrically opposed cost 
trends were detected with respect to the number of co-occurring diseases. While in 
one group containing hypertension, joint arthrosis, diabetes, gout, anxiety and lower 
limb varicosis cost increased with the number of co-occurring diseases, in a sec-
ond group including severe hearing loss, asthma/COPD, osteoporosis, neuropathies, 
Parkinson’s disease and chronic ischemic heart disease cost decreased. Diversities 
between groups were also found in the results indicated by diametrically opposed 
influence of single diseases. ConClusions: Our results indicate existing unob-
served heterogeneity in costs among patients suffering from multimorbidity with 
different combinations of single diseases which would remain unconsidered using 
standard regression techniques. Especially different costs trends were detected with 
regard to the number and nature of co-existing diseases.
ReseaRch on MeThoDs – Databases & Management Methods
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‘Real-woRlD’ ManageMenT of TubeRous scleRosis coMPlex (Tsc) in The 
uniTeD kingDoM
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1IMS Health, London, UK, 2Novartis Pharmaceuticals UK Limited, Frimley, UK, 3Novartis 
Pharmaceuticals Corporation, East Hanover, NJ, USA
objeCtives: TSC is a multi-system genetic disorder associated with benign lesions 
throughout the body, neurological manifestations, and impaired cognition. As many 
as 8000 people in the UK may have TSC; many cases likely go undiagnosed. Long-
term morbidity and treatment burden associated with TSC are significant, suggest-
ing substantial economic burden. This preliminary study assessed presentation 
patterns of select TSC manifestations in CPRD. Methods: TSC patients were retro-
spectively identified in CPRD (Read: PK5.00) and linked Hospital Episodes Statistics 
(HES; ICD-10: Q85.1) databases. CPRD includes over 5 million active patients from UK 
primary care practices (~8% coverage). A total of 55% of practices (375) are linked to 
HES, allowing events in secondary care to be analysed (e.g. hospitalisations, proce-
dures). Patients not linked to HES were excluded. Available history was extracted for 
each patient; descriptive statistics for select TSC-related diagnoses and procedures 
are presented. All ages reported below are median values. Results: A total of 244 
patients (49% male) with a TSC diagnosis were identified; age at diagnosis was 8 
years, with 70% under 18 years. Patient data history was 20 years; 3 and 11 years 
pre/post initial TSC diagnosis. By age 4, 72% had a record of epilepsy; by 16 years, 
9% had a record of subependymal giant-cell astrocytoma (SEGA); by 18 years, 1% 
had obstructive hydrocephalus; by 43 years, 4% had renal angiomyolipoma (AML) 
[median age at initial recorded diagnosis]. ConClusions: Preliminary analyses 
affirm the utility of CPRD in a real-world study of TSC, and the many emergent TSC-
related manifestations, in a longitudinal fashion. Data are suggestive of evolving 
diagnostic and treatment patterns (30% adults) and may highlight a need for better 
coordination of adult care. Relatively low prevalence of AML was unexpected and 
sents almost 3.4% of the country’s GDP (2010). In terms of employment 23.000 are 
directly employed in the sector, while the total benefit for the Greek economy (both 
direct and indirect) is estimated to approximately 132.000 jobs. Finally, the industry 
accounts for nearly € 400 million tax revenue, half of which affects the economy 
directly. ConClusions: Taking these effects in consideration it stems that for every 
€ 1 of Value added in the production / distribution of the pharmaceutical sector some 
€ 2.6 of Value added is created as an indirect effect and € 5.3 as an induced effect. 
Additionally every job position in the sector in the pharmaceutical (production / 
distribution) sector supports 2.5 jobs due to indirect effects and almost 6 jobs in the 
economy. Finally, for every € 1 in tax revenue provided by the sector, an additional 
€ 1.6 is generated though indirect effect and a total of € 2.2 if the induced effect is 
taken into consideration.
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an assessMenT of The use of uTiliTy DaTa in long-TeRM cosT-
effecTiveness MoDels of liPiD loweRing TheRaPies
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objeCtives: To determine through a literature review how economic evaluations 
incorporate utility data into models when estimating long-term cost-effectiveness 
of lipid lowering therapies in primary and/or secondary cardiovascular disease 
(CVD) prevention. Methods: We used MEDLINE to identify published articles 
reporting cost-effectiveness models. Inclusion criteria included: English language 
articles published from 2000-2013, studies in adults ≥ 18 years old, studies assess-
ing statins or ezetimibe for primary and/or secondary CVD prevention, and studies 
in the US, Canada, UK, Spain, Germany, Australia, Sweden, France, and Italy. Two 
researchers independently identified articles and disagreements were resolved by 
consensus. Results: Sixty-one studies fulfilled the inclusion criteria. Forty-eight 
studies assessed the long-term cost-effectiveness (≥ 10 years) of lipid-lowering ther-
apy— 20 studies were in primary CVD prevention, 19 were in secondary prevention, 
and 9 were in both primary and secondary prevention. 36/48 studies incorporated 
utility parameters into their models. 23/36 models differentiated short-term ver-
sus long-term utility impact of cardiovascular events. Eleven models were able 
to differentiate between short-term and long-term utilities through model struc-
ture, where separate health states were created for events versus post-events (e.g., 
stroke versus post-stroke), and utility values could be assigned to these health states 
accordingly. Twelve models were able to differentiate short-term versus long-term 
utilities by changing the model inputs, where different utility values were applied 
to a health state according to length of time after the event (e.g., event year versus 
subsequent years for a health state, or < 6 months versus > 6 months from time of 
event). Eleven models accounted for the occurrence of multiple events by applying 
disutilities or combining utilities multiplicatively for patients experiencing ≥ 1 event 
over time. ConClusions: Around two-thirds of the published long-term models 
differentiated short-term versus long-term utility impacts of cardiovascular events 
through model structure or utility inputs, which should be incorporated into future 
models on this topic.
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objeCtives: To build an Excel calculator, taking demographic and clinical charac-
teristics of rheumatoid arthritis (RA) patients in Turkey, and estimate the annual 
health care costs. Methods: 2009-2011 data from MEDULA, the Turkish national 
health insurance database, was used for the study. RA patients (ages 18-99) were 
identified for the identification period (June 1, 2010 - December 31, 2010) using 
International Classification of Disease Tenth Revision Clinical Modification (ICD-
10-CM) codes. Patients were grouped as prevalent and incident cases and required 
to have two RA diagnoses at least 60 days apart. In order to estimate risk-adjusted 
total annual costs for prevalent and incident cases, generalized linear models 
(GLMs) were used. Patients’ demographic and clinical characteristics were factors 
to determine the expected annual cost value, with coefficients of the charac-
teristics built in the Excel calculator. A marginal effects table was created after 
GLM estimation by using such calculation. Results: A total of 2,613 patients 
met all inclusion criteria, of which 693 were incident and 1,920 prevalent cases. 
Patients’ demographic and clinical characteristics were entered into the Excel 
calculator. Risk-adjusted annual total costs were calculated at € 2,021 for prevalent 
cases and € 1,818 for incident cases. The most expensive contributor to annual 
expenditures was prior biologic use for both groups. Prevalent patients who were 
prescribed disease-modifying anti-rheumatic drugs (DMARDs) in the baseline 
period incurred € 5,898 more costs than those who were not. For incident cases, 
male patients incurred lower costs (€ 1,818 - € 708 = € 1,110), whereas respiratory 
comorbid conditions increased the total expected health care cost of incident RA 
patients by € 916 (€ 1,818 + € 916 = € 2,734). ConClusions: In outcomes research, an 
Excel calculator serves as an important tool to estimate and compare RA-related 
health care costs.
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uncoveRing The gaP beTween MoDel valiDaTion RecoMMenDaTions 
anD PRacTice
Kleintjens J., Akpo H.
Deloitte, Diegem, Belgium
objeCtives: Health technology agencies and payers rely on economic models to 
evaluate the value of new treatments. It is therefore critical to ensure the scientific 
credibility of these models through validation, which is also required by NICE since 
